240 related articles for article (PubMed ID: 28743242)
1. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
3. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
Chen J; Zhao QW; Shi GM; Wang LR
J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
[TBL] [Abstract][Full Text] [Related]
4. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
Yuan Z; Li J; Hu R; Jiao Y; Han Y; Weng Q
Sci Rep; 2015 Nov; 5():16482. PubMed ID: 26585370
[TBL] [Abstract][Full Text] [Related]
5. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
[TBL] [Abstract][Full Text] [Related]
6. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
8. Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis.
Sun JY; Zhang CY; Zhang ZJ; Dong YF; Zhang AL; Wang ZW; Mei XL
Asian Pac J Cancer Prev; 2012; 13(9):4783-8. PubMed ID: 23167420
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
[TBL] [Abstract][Full Text] [Related]
12. Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.
Dong J; Wang X; Yu Y; Yan X; Cui JW
Chin Med J (Engl); 2018 Aug; 131(16):1904-1908. PubMed ID: 30082520
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
14. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
[TBL] [Abstract][Full Text] [Related]
15. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
16. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
17. Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population.
Wu D; Jiang H; Gu Q; Zhang D; Li Z
Tumour Biol; 2013 Oct; 34(5):3265-9. PubMed ID: 23780894
[TBL] [Abstract][Full Text] [Related]
18. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.
Zhang Z; Xiang Q; Mu G; Xie Q; Chen S; Zhou S; Hu K; Cui YM
Medicine (Baltimore); 2018 Nov; 97(45):e12996. PubMed ID: 30407287
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]